These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Promising immunotherapy technique. Fillon M J Natl Cancer Inst; 2012 Oct; 104(20):1528-9. PubMed ID: 23044382 [No Abstract] [Full Text] [Related]
4. Cancer immunotherapy. White RL; Amin A Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920 [TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines. Nakamura Y Clin Adv Hematol Oncol; 2011 Oct; 9(10):778-9. PubMed ID: 22252581 [No Abstract] [Full Text] [Related]
6. Promising Immuno-Oncology Treatments Beyond the 2018 Nobel Prize. Castelo-Branco L; Silva IP; Canhão H; Awada A Acta Med Port; 2019 Apr; 32(4):251-257. PubMed ID: 31067417 [No Abstract] [Full Text] [Related]
7. [Immunotherapy: Activation of a system not a pathway]. Bernichon E; Rancoule C; Vallard A; Langrand-Escure J; Mery B; Guy JB; Magné N Bull Cancer; 2017 May; 104(5):462-475. PubMed ID: 28477871 [TBL] [Abstract][Full Text] [Related]
8. New therapies for castration-resistant prostate cancer. Longo DL N Engl J Med; 2010 Jul; 363(5):479-81. PubMed ID: 20818868 [No Abstract] [Full Text] [Related]
9. The anti-idiotype vaccines for immunotherapy. Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733 [TBL] [Abstract][Full Text] [Related]
10. The potential of melanoma antigen expression in cancer therapy. Gillespie AM; Coleman RE Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Ascierto PA; Kalos M; Schaer DA; Callahan MK; Wolchok JD Clin Cancer Res; 2013 Mar; 19(5):1009-20. PubMed ID: 23460532 [TBL] [Abstract][Full Text] [Related]
13. Cancer Vaccines. DeMaria PJ; Bilusic M Hematol Oncol Clin North Am; 2019 Apr; 33(2):199-214. PubMed ID: 30832995 [TBL] [Abstract][Full Text] [Related]
14. Future of immunotherapy drug combinations and biomarkers. Schmidt C J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694 [No Abstract] [Full Text] [Related]
15. Therapeutic gene modified cell based cancer vaccines. Kozłowska A; Mackiewicz J; Mackiewicz A Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846 [TBL] [Abstract][Full Text] [Related]
16. Current developments of immunotherapy in the clinic. Antonia S; Mulé JJ; Weber JS Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403 [TBL] [Abstract][Full Text] [Related]
17. Rethinking therapeutic cancer vaccines. Nat Rev Drug Discov; 2009 Sep; 8(9):685-6. PubMed ID: 19721436 [No Abstract] [Full Text] [Related]
18. Recent advances using anti-CTLA-4 for the treatment of melanoma. Sarnaik AA; Weber JS Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898 [TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy: a treatment for the masses. Blattman JN; Greenberg PD Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]